- Describe the rationale for focal/partial gland therapy of prostate cancer.
- Identify optimal candidate for focal treatments.
- Evaluate the latest evidence on oncological and functional outcomes of focal therapy.
- Describe surveillance strategies post-focal therapy of prostate cancer.
- Prevent, identify and manage complications of focal therapy.
- Describe various steps of transperineal interventions and treatment planning for focal therapy using different modalities.
- Describe the indications, preoperative evaluation, surgical steps-procedure, and expected patient outcomes for various minimally invasive operations for BPH.
Interprofessional Continuing Education – Rush Accreditation
In support of improving patient care, Rush University Medical Center is jointly accredited by the American Nurses Credentialing Center (ANCC), the Accreditation Council for Pharmacy Education (ACPE), and the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing education for the healthcare team.
Rush University Medical Center designates this live activity for a maximum of 9.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.
To claim Continuing Education Credit, attendees must:
- Attend the entire session;
- Evaluate and Generate a certificate according to the instructions.
Unapproved Uses of Drugs/Devices: In accordance with requirements of the FDA, the audience is advised that information presented in this continuing medical education activity may contain references to unlabeled or unapproved uses of drugs or devices. Please refer to the FDA approved package insert for each drug/device for full prescribing/utilization information.
It is the policy of the Rush University Center for Innovative and Lifelong Learning to ensure that its CE activities are independent, free of commercial bias and beyond the control of persons or organizations with an economic interest in influencing the content of CE. Everyone who is in a position to control the content of an educational activity must disclose all relevant financial relationships with any commercial interest (including but not limited to pharmaceutical companies, biomedical device manufacturers, or other corporations whose products or services are related to the subject matter of the presentation topic) within the preceding 12 months.
The course directors, planners and faculty of this activity have the following relevant financial relationships to disclose.
|Andre Abreu, MD||Proctor, Steba Biotech|
|Hashim Ahmed, MD||Research Grant, Sonacare Inc., Sophiris, Boston Scientific, Angiodynamics, Trod Medical; Consultant, Sophiris, Boston; Member, Speakers Bureau, Sophiris, Boston|
|Mihir Desai, MD||Stockholder, Procept Biorobotics|
|Christopher Dixon, MD||Research Grant, Institutional, Franics Medical; Member, Speakers Bureau, Francis Medical, Boston Scientific, Inc.,|
|Mark Emberton, MD FRCS||Member, Speakers Bureau, Consultant, STEBA Biotech, Sonacare Medical Inc., Profound Medical, Exact Imaging, Minomic Medical, Proteomix, Medical Imaging Partnerships|
|Arvin George, MD||Research Grant, Philips Medical, Nanospectra Biosciences; Consultant, TROD Medical|
|Inderbir Gill, MD||None|
|Amin Herati, MD||Consultant, Dadikit|
|Amar Kishan, MD||Research Grant, ViewRay, Inc., Consultant, Varian Medical System, Inc.|
|Amir Lebastchi, MD||None|
|Leonard Marks, MD***||Co-founder, Avenda Health|
|Peter Pinto, MD||Philips/In Vivo Inc pays royalties to NIH for a licensing agreement, NIH then pays royalties to Dr. Pinto. NIH and Philips have a CRADA. NIH has intellectual property in the field, including among other patents and patent applications, Patent: “System And Method For Prostate Cancer Detection And Distribution Mapping” US Patent number: 8,447,384 and “System And Method For Computer Aided Cancer Detection Using T2-weighted And High-value Diffusion-weighted Magnetic Resonance Imaging” US Patent number: 10,215,830 with inventors/author, Brad Wood and Peter Pinto. NIH and Philips (In Vivo Inc) have a licensing agreement.|
|Thomas Polascik, MD, FACS||None|
|Art Rastinehad, DO||None|
|Stephen Scionti, MD||None|
|Abhinav Sidana, MD||None|
|Mohummad M. Siddiqui, MD||None|
|Samir Taneja, MD||Royalty, Elsevier; Stockholder, Johnson and Johnson, Abbvie; Consultant, Trod Medical, Insightec, Francis Medical, Janssen; Scientific Investigator, MDxHealth|
|Sadhna Verma, MD||None|
|Sri Vourganti, MD||Consultant, Angiodynamics, Ambu, Astellas;|
|Jonathan N Warner,MD||Consultant, Olympus|
|James Wysock, MD||None|
The following sessions will not receive continuing education credit. This is in no way a reflection of the integrity or quality of the content.
Saturday, October 3, 2020
- Session 2: Focal Therapy Gauntlet: Battle of Focal Therapy Ablation Modalities
- State-of-the-Art BPH Management: Live Interactive Breakout
- In-Office Transperineal Interventions: In-Office Transperineal Interventions: Live Interactive Breakout Session
- Fusion Guided Ablation: Fusion Guided Ablation: Live Interactive Breakout Session
Sunday, October 4, 2020
- Session 4: Surveillance and Outcome Assessment After Focal Therapy: PSA and Biomakers
- Session 5: Focal Therapy Challenges and Case Discussions: Live Case Discussions
- Session 6: Starting A Focal Therapy Program: Billing and Reimbursement
- Session 7: What’s on the Horizon: New Modality 1
- Session 7: What’s on the Horizon: New Modality 2
All other individuals in control of content have stated they have no relevant financial disclosures.